Publications by authors named "C M Creticos"
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.
Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).
Objective: We describe the first case of HIV-1 infection in the setting of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis to occur in the real world.
Design: Case report.
Methods: Electronic medical records were reviewed to assess patient history and CAB-LA administration details.
Cryptococcal Meningitis in an Immunocompetent Patient with a Ventriculo-Pleural Shunt.
Case Rep Infect Dis
April 2020
Cryptococcal meningitis is the most common form of infection caused by Cryptococcus yeast species, followed by pulmonary infection. It is an opportunistic infection seen in patients with impaired cell immunity, most frequently in HIV patients and solid organ transplant recipients; however, it can occur in patients with no apparent immunodeficiency. We describe the case of meningitis in an immunocompetent patient with aseptic cerebrospinal fluid analysis which highlights the heterogeneity of this disease.
View Article and Find Full Text PDFCo-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Lancet HIV
June 2019
Article Synopsis
- The study compares the long-term efficacy, safety, and tolerability of a single-tablet HIV treatment (bictegravir, emtricitabine, and tenofovir alafenamide) against a dual regimen (dolutegravir with emtricitabine and tenofovir alafenamide) over 96 weeks.
- Conducted as a randomized, double-blind trial across 126 centers in 10 countries, the study involved treatment-naive adults with HIV-1 and followed a strict inclusion criteria, ensuring participants had specific health parameters.
- Results showed that both treatment groups yielded similar rates of achieving undetectable HIV levels, demonstrating the new single-tablet regimen's effectiveness over the monitored timeframe.
Background: Switching from therapy based on a boosted protease inhibitor to bictegravir, emtricitabine, and tenofovir alafenamide could avoid drug interactions and unwanted side-effects in virologically suppressed adults with HIV-1 infection, while maintaining a high barrier to resistance and providing a simplified once-daily, single-tablet regimen. Here, we report 48 week results of a phase 3 study investigating this switch.
Methods: In this multicentre, randomised, open-label, active-controlled, non-inferiority, phase 3 trial, adults with HIV-1 infection were enrolled at 121 outpatient centres in ten countries.